Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan-Reference-Cited by-同舟云学术

Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan

Published:2021-06 Issue:6 Volume:27 Page:506.e1-506.e10
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Wakase Shiho,Teshima Takanori,Zhang Jie,Ma Qiufei,Fujita Taizo,Yang Hongbo,Chai Xinglei,Qi Cynthia Z.,Liu Qing,Wu Eric Q.,Igarashi Ataru

Funder

Novartis Pharmaceuticals Corp

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference56 articles.

1. Pathophysiology and molecular aspects of diffuse large B-cell lymphoma;Gouveia;Rev Bras Hematol Hemoter,2012

2. Differences in incidence and trends of haematological malignancies in Japan and the United States;Chihara;Br J Haematol,2014

3. Relapsed/refractory diffuse large B-cell lymphoma;Friedberg;Hematology Am Soc Hematol Educ Program,2011

4. Japanese Society of Hematology. Hematopoietic tumor treatment guidelines, 2018 edition. Available at: http://www.jshem.or.jp/gui-hemali/2_5.html. Accessed June 12, 2020.

5. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study;Van Den Neste;Bone Marrow Transplant,2017

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review;Value in Health;2024-08

2. A Review of the Cost-Effectiveness Evidence for FDA-Approved Cell and Gene Therapies;Human Gene Therapy;2024-06-01

3. Cost–effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan;Future Oncology;2024-04-10

4. CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis;Medical Decision Making;2024-03-14

5. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results;Journal of Medical Economics;2024-02-13